Neuresta is a biopharmaceutical startup company dedicated to developing new effective therapies for people with chronic pain. Since persistent pain is usually limited to specific areas of the body, our strategy is to develop and advance injectable medications that offer prolonged local analgesia without systemic side effects. We derive these medications through genetic re-engineering of Botulinum Neurotoxins (BoNT), which are potent long-lasting nerve blockers. Our proprietary platform is designed for rapid assembly of active BoNT complexes from separately produced recombinant fragments. This innovative technology permits combinatorial use of functional domains from different BoNT isoforms and/or genetic modification of these isoforms for desired potency and cellular targeting specificity. Unlike natural BoNT products, our lead candidates are expected to alleviate pain without paralyzing muscles.
In early 2021, Neuresta launched a comprehensive preclinical development study in collaboration with the National Center for Advancing Translational Sciences, part of the US National Institutes of Health. NCATS’ mission is to turn promising science observations into health solutions more efficiently. This collaboration focuses on neuropathic pain and operates under the umbrella of the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, to end the opioid crisis.
We currently seek new partnerships to accelerate this program. We also strive to expand the application of modified BoNT variants to treat the full spectrum of chronic pain conditions. If you are interested in partnering with Neuresta, please contact us at: email@example.com.